PI3K/AKT/mTOR通路
乳腺癌
蛋白激酶B
癌症
癌症研究
癌变
医学
靶向治疗
信号转导
生物信息学
肿瘤科
生物
内科学
细胞生物学
作者
Kunrui Zhu,Yanqi Wu,Ping He,Yu Fan,Xiaorong Zhong,Hong Zheng,Ting Luo
出处
期刊:Cells
[MDPI AG]
日期:2022-08-12
卷期号:11 (16): 2508-2508
被引量:42
标识
DOI:10.3390/cells11162508
摘要
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and confer worse prognosis in breast cancer patients. The inhibitors targeting three key nodes of these pathways, PI3K, AKT and mTOR, are continuously developed. For breast cancer patients to truly benefit from PAM pathway inhibitors, it is necessary to clarify the frequency and mechanism of abnormal alterations in the PAM pathway in different breast cancer subtypes, and further explore reliable biomarkers to identify the appropriate population for precision therapy. Some PI3K and mTOR inhibitors have been approved by regulatory authorities for the treatment of specific breast cancer patient populations, and many new-generation PI3K/mTOR inhibitors and AKT isoform inhibitors have also been shown to have good prospects for cancer therapy. This review summarizes the changes in the PAM signaling pathway in different subtypes of breast cancer, and the latest research progress about the biomarkers and clinical application of PAM-targeted inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI